Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Synyi Closes $61 Million Round for AI-based Medical Data Analysis

publication date: Dec 28, 2020

Synyi AI, a Shanghai company that offers artificial intelligence technology for medical treatment, closed a $61 million Series D round led by CICC Alpha, a direct investment platform of China International Capital Corporation (CICC). Synyi AI has been backed by China internet company Tencent, which participated in the funding along with Sunshine Insurance Group. Founded in 2016, Synyi AI provides hospitals, medical institutions and drug makers with AI and big data technologies to improve their efficiency in clinical research, clinical diagnosis/treatment and hospital management. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital